GI 5005

Drug Profile

GI 5005

Alternative Names: GI-5005; Tarmogen

Latest Information Update: 14 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlobeImmune
  • Class Antivirals; Hepatitis C vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 03 Nov 2010 GlobeImmune receives grants under the Federal Therapeutics Discovery Projects programme for GI 5005 development in Hepatitis C
  • 30 Oct 2010 Efficacy data from a phase IIb trial (GI-5005-02) in Hepatitis C presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2010)
  • 28 Oct 2010 GlobeImmune expands phase IIb trial (GI-5005-02) for treatment-naive Hepatitis C to include patients with IL28B T/T genotype
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top